.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Citi
Medtronic
Farmers Insurance
Julphar
Teva
Cipla
Express Scripts
Merck

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Formulations containing hyaluronic acid
Abstract:The invention relates to a method of rapidly transporting a drug to the epidermis and accumulating and maintaining the drug therein for a prolonged period of time comprising administration of a therapeutically efective non-toxic amount of the drug with an effective amount of hyaluronic acid.
Inventor(s): Falk; Rudolf Edger (Toronto, CA), Asculai; Samuel Simon (Toronto, CA), Hochman; David (Thornhill, CA), Purschke; Don (Toronto, CA), Klein; Ehud Shmuel (Givat Savyon, IL), Harper; David William (Oakville, CA)
Assignee: Hyal Pharmaceutical Corporation (Mississauga, CA)
Filing Date:Jun 06, 1995
Application Number:08/466,714
Claims:1. Pharmaceutical compositions from which effective non-toxic dosage amounts may be taken and applied to the skin or exposed tissue of a human, each effective dosage amount comprising pharmaceutical excipients suitable for topical application, an effective non-toxic dosage amount of a drug to treat a disease or condition of the skin or exposed tissue of a human involving a pathology, and an effective non-toxic dosage amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof sufficient to transport the drug into the epidermis or exposed tissue of the disease or condition involving a pathology to be treated wherein the dosage amount of the composition accumulates and remains in the epidermis for a prolonged period of time and which is systemic independent acting and wherein the form of hyaluronic acid present is between about 1% and about 3% by weight of the dosage amount and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons and greater than 150,000 daltons.

2. A method of rapidly transporting a drug to the epidermis and accumulating and maintaining the drug therein for a prolonged period of time, the method comprising topically administering a composition comprising together with pharmaceutical excipients suitable for topical application, a therapeutically effective non-toxic dosage amount of a drug to treat a disease or condition of the skin or exposed tissue involving a pathology, and an amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and its non-toxic salts and combinations thereof sufficient to facilitate the rapid transport of the drug to the site in the skin or tissue of the disease or condition to the site of the pathology or trauma to accumulate there and be retained there for a prolonged period of time and wherein the form of hyaluronic acid is administered in excess of 5 mg. per cm.sup.2, and wherein the molecular weight of the form of hyaluronic acid is less than 750,000 daltons and greater than 150,000 daltons.

3. The method of claim 2 wherein the form of hyaluronic acid is sodium hyaluronate.

4. The composition of claim 1 wherein the drug present is between about 1% and about 5% by weight of the dosage amount and the form of hyaluronic acid is sodium hyaluronate.

5. The method of claim 2 wherein the form of hyaluronic acid present is between about 1% and about 3% by weight of the dosage amount.

6. The method of claim 2 wherein the drug present is between about 1% and about 5% by weight of the dosage amount.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Fuji
QuintilesIMS
Queensland Health
Dow
Chinese Patent Office
Express Scripts
Harvard Business School
Daiichi Sankyo
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot